In vitro and in vivo studies in gemcitabine-resistant pancreatic cancer cells have shown that Rg3 can activate PTEN signaling by upregulation of CASC2, thereby reducing cell proliferation and tumor growth [147]. This evidence concerns the gene CASC2 and familial pancreatic carcinoma.